Payment overview · 2025
General Payments
$3,142.99
216 reported records · 19 companies
Healthcare provider profile · identity verified
Marcelo Marin, DNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · ENGLEWOOD, NJ · NPI 1730582800
Verified facts
What the public records show
CMS Open Payments records show Marcelo Marin, DNP received $3,142.99 in general payments during 2025 across 216 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Ingrezza, Nurtec Odt, Qulipta, Relistor, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ubrelvy by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Relistor by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $717.61 | 22.8% | 53 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $377.45 | 12.0% | 28 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $331.93 | 10.6% | 26 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $328.29 | 10.4% | 19 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $296.00 | 9.4% | 18 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $267.21 | 8.5% | 17 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $198.92 | 6.3% | 17 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $120.39 | 3.8% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $115.95 | 3.7% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.48 | 2.6% | 5 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $58.19 | 1.9% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $37.93 | 1.2% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $35.96 | 1.1% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.64 | 1.1% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $34.10 | 1.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.00 | 1.1% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$29.08 | 0.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.29 | 0.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.57 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,998.53 | 213 |
| Education | $111.49 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32.97 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $606.12 | 52 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $377.45 | 28 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $348.59 | 22 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $296.00 | 18 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $275.91 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $267.21 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $211.35 | 19 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $129.52 | 11 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $120.39 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.09 | 9 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $115.95 | 7 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $82.48 | 5 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $58.19 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.69 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.38 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| Xadago Normalized: xadago |
Drug | MDD US Operations, LLC | $31.75 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $29.08 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $8.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 140 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 148 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
148 | 30 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
140 | 31 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 716 | 164 |
| Gabapentin | Gabapentin | 671 | 127 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 571 | 100 |
| Tramadol Hcl | Tramadol Hcl | 427 | 76 |
| Amitriptyline Hcl | Amitriptyline Hcl | 384 | 89 |
| Meclizine Hcl | Meclizine Hcl | 366 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 364 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 308 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 299 | 28 |
| Naproxen | Naproxen | 286 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 255 | 43 |
| Topiramate | Topiramate | 219 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 157 | 30 |
| Mirtazapine | Mirtazapine | 157 | 29 |
| Omeprazole | Omeprazole | 154 | 36 |
| Ubrelvy | Ubrogepant | 148 | 30 |
| Nurtec Odt | Rimegepant Sulfate | 140 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 132 | 19 |
| Levetiracetam | Levetiracetam | 129 | 21 |
| Lidocaine | Lidocaine | 125 | 37 |
| Ztlido | Lidocaine | 121 | 27 |
| Ibuprofen | Ibuprofen | 108 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 22 |
| Trazodone Hcl | Trazodone Hcl | 89 | 29 |
| Emgality Pen | Galcanezumab-Gnlm | 84 | 14 |
| Lamotrigine | Lamotrigine | 84 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 81 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 77 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 77 | 21 |
| Ondansetron Odt | Ondansetron | 66 | 11 |
| Pregabalin | Pregabalin | 65 | 19 |
| Memantine Hcl | Memantine Hcl | 61 | 14 |
| Baclofen | Baclofen | 58 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 13 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 56 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | 12 |
| Alprazolam | Alprazolam | 45 | 11 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Meloxicam | Meloxicam | 33 | 14 |
| Primidone | Primidone | 33 | 12 |
| Nabumetone | Nabumetone | 32 | suppressed |
| Belsomra | Suvorexant | 29 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Relistor | Methylnaltrexone Bromide | 23 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Keppra | Levetiracetam | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,142.99 · 216 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, Apokyn, Auvelity, BOTOX, BRIUMVI, Briviact, CARDIVA VASCADE MVP VVCS 6-12F, ELYXYB - CELECOXIB, INGREZZA, KESIMPTA, NUPLAZID, NURTEC ODT, Nayzilam, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, RELISTOR, REXULTI, Symbravo, UBRELVY, VALTOCO, VRAYLAR, VYALEV, VYEPTI, Xadago, ZAVZPRET, ZEPOSIA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error